Trial Outcomes & Findings for Are Bright Lights and Regulated Sleep Effective Treatment for Depression? (NCT NCT03010488)

NCT ID: NCT03010488

Last Updated: 2021-03-23

Results Overview

Independent Evaluator's Week 6 17-item Hamilton Rating Scale for Depression Summary Score. The 17-item Hamilton is the standard measure of depression severity for clinical trials of antidepressants and was chosen as the primary outcome measure over other depression rating scales to ensure compatibility of study results with our meta-analyses and ongoing studies of expectancy. Although the Hamilton list 24 items, the scoring is based on both the first 17 items and the full 24 items. sum of the scores of the first 17 items (range from 0 to 54): 0-7 = NORMAL 8-13 = Mild Depression 14-18 = Moderate Depression 19-22 = Severe Depression \>=23 = Very Severe Depression

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

44 participants

Primary outcome timeframe

Week 6

Results posted on

2021-03-23

Participant Flow

Participant milestones

Participant milestones
Measure
Rapid Sleep Shift
Assigned Sleep Times designed to shift sleep times over several days from Baseline to desired through morning light therapy while wearing clear goggles. Morning Light Therapy: 10,000 Lux light for 30 minutes through a light box each morning at patient's desired wake up time. Assigned Sleep Times: Sleep times will be assigned to subjects that will allow them to drive their regular sleep times closer to those they determine to be optimal at study initiation. Goggles: Subjects will wear goggles during saliva collection and Bright Light Therapy
Gradual Sleep Shift
Assigned Sleep Times designed gradually shift sleep from current to desired sleep times while using morning light therapy while wearing amber (blue blocking) goggles. Morning Light Therapy: 10,000 Lux light for 30 minutes through a light box each morning at patient's desired wake up time. Assigned Sleep Times: Sleep times will be assigned to subjects that will allow them to drive their regular sleep times closer to those they determine to be optimal at study initiation. Goggles: Subjects will wear goggles during saliva collection and Bright Light Therapy
Overall Study
STARTED
22
22
Overall Study
COMPLETED
17
15
Overall Study
NOT COMPLETED
5
7

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Are Bright Lights and Regulated Sleep Effective Treatment for Depression?

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Rapid Sleep Shift
n=22 Participants
Assigned Sleep Times designed to shift sleep times over several days from Baseline to desired through morning light therapy while wearing clear goggles. Morning Light Therapy: 10,000 Lux light for 30 minutes through a light box each morning at patient's desired wake up time. Assigned Sleep Times: Sleep times will be assigned to subjects that will allow them to drive their regular sleep times closer to those they determine to be optimal at study initiation. Goggles: Subjects will wear goggles during saliva collection and Bright Light Therapy
Gradual Sleep Shift
n=22 Participants
Assigned Sleep Times designed gradually shift sleep from current to desired sleep times while using morning light therapy while wearing amber (blue blocking) goggles. Morning Light Therapy: 10,000 Lux light for 30 minutes through a light box each morning at patient's desired wake up time. Assigned Sleep Times: Sleep times will be assigned to subjects that will allow them to drive their regular sleep times closer to those they determine to be optimal at study initiation. Goggles: Subjects will wear goggles during saliva collection and Bright Light Therapy
Total
n=44 Participants
Total of all reporting groups
Age, Continuous
37.8 years
STANDARD_DEVIATION 14.3 • n=99 Participants
38.8 years
STANDARD_DEVIATION 16.4 • n=107 Participants
38.3 years
STANDARD_DEVIATION 15.2 • n=206 Participants
Sex: Female, Male
Female
12 Participants
n=99 Participants
12 Participants
n=107 Participants
24 Participants
n=206 Participants
Sex: Female, Male
Male
10 Participants
n=99 Participants
10 Participants
n=107 Participants
20 Participants
n=206 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Asian
0 Participants
n=99 Participants
2 Participants
n=107 Participants
2 Participants
n=206 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Black or African American
2 Participants
n=99 Participants
1 Participants
n=107 Participants
3 Participants
n=206 Participants
Race (NIH/OMB)
White
17 Participants
n=99 Participants
17 Participants
n=107 Participants
34 Participants
n=206 Participants
Race (NIH/OMB)
More than one race
1 Participants
n=99 Participants
0 Participants
n=107 Participants
1 Participants
n=206 Participants
Race (NIH/OMB)
Unknown or Not Reported
2 Participants
n=99 Participants
2 Participants
n=107 Participants
4 Participants
n=206 Participants
Region of Enrollment
United States
22 participants
n=99 Participants
22 participants
n=107 Participants
44 participants
n=206 Participants

PRIMARY outcome

Timeframe: Week 6

Population: Due to rater availability we weren't able to get independent evaluations on all participants. The numbers listed or the number we were able to get independent evaluations on.

Independent Evaluator's Week 6 17-item Hamilton Rating Scale for Depression Summary Score. The 17-item Hamilton is the standard measure of depression severity for clinical trials of antidepressants and was chosen as the primary outcome measure over other depression rating scales to ensure compatibility of study results with our meta-analyses and ongoing studies of expectancy. Although the Hamilton list 24 items, the scoring is based on both the first 17 items and the full 24 items. sum of the scores of the first 17 items (range from 0 to 54): 0-7 = NORMAL 8-13 = Mild Depression 14-18 = Moderate Depression 19-22 = Severe Depression \>=23 = Very Severe Depression

Outcome measures

Outcome measures
Measure
Rapid Sleep Shift
n=18 Participants
Assigned Sleep Times designed to shift sleep times over several days from Baseline to desired through morning light therapy while wearing clear goggles. Morning Light Therapy: 10,000 Lux light for 30 minutes through a light box each morning at patient's desired wake up time. Assigned Sleep Times: Sleep times will be assigned to subjects that will allow them to drive their regular sleep times closer to those they determine to be optimal at study initiation. Goggles: Subjects will wear goggles during saliva collection and Bright Light Therapy
Gradual Sleep Shift
n=15 Participants
Assigned Sleep Times designed gradually shift sleep from current to desired sleep times while using morning light therapy while wearing amber (blue blocking) goggles. Morning Light Therapy: 10,000 Lux light for 30 minutes through a light box each morning at patient's desired wake up time. Assigned Sleep Times: Sleep times will be assigned to subjects that will allow them to drive their regular sleep times closer to those they determine to be optimal at study initiation. Goggles: Subjects will wear goggles during saliva collection and Bright Light Therapy
17-Item Hamilton Rating Scale for Depression Score (Independent Evaluator)
8.66 units on a scale
Standard Deviation 6.09
10.46 units on a scale
Standard Deviation 7.79

SECONDARY outcome

Timeframe: Week 6

Population: Due to rater availability we weren't able to get independent evaluations on all participants. The numbers listed or the number we were able to get independent evaluations on.

Sleep Efficiency (percentage of time spent sleeping during target sleep period) as measured by activity monitor and sleep logs. Sleep logs: Patients were instructed to record all sleep periods in the daily log by marking boxes representing 15-minute intervals. They were also requested to wear the Actigraph activity monitor at all times except for bathing, swimming, or any other activities requiring immersion of the wrist. In addition, patients were provided with schedules delineating their allowed sleep time each day. Patients chose their target sleep times (an eight-hour time they desired their sleep to occur) and completed the Morningness-Eveningness Questionnaire (MEQ) to estimate the timing of their circadian clocks, including ideal sleep and wake-up times.

Outcome measures

Outcome measures
Measure
Rapid Sleep Shift
n=7 Participants
Assigned Sleep Times designed to shift sleep times over several days from Baseline to desired through morning light therapy while wearing clear goggles. Morning Light Therapy: 10,000 Lux light for 30 minutes through a light box each morning at patient's desired wake up time. Assigned Sleep Times: Sleep times will be assigned to subjects that will allow them to drive their regular sleep times closer to those they determine to be optimal at study initiation. Goggles: Subjects will wear goggles during saliva collection and Bright Light Therapy
Gradual Sleep Shift
n=7 Participants
Assigned Sleep Times designed gradually shift sleep from current to desired sleep times while using morning light therapy while wearing amber (blue blocking) goggles. Morning Light Therapy: 10,000 Lux light for 30 minutes through a light box each morning at patient's desired wake up time. Assigned Sleep Times: Sleep times will be assigned to subjects that will allow them to drive their regular sleep times closer to those they determine to be optimal at study initiation. Goggles: Subjects will wear goggles during saliva collection and Bright Light Therapy
Participant Sleep Efficiency
76.43 percentage of time
Standard Deviation 10.82
68.23 percentage of time
Standard Deviation 28.27

Adverse Events

Rapid Sleep Shift

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Gradual Sleep Shift

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

David Hellerstein

New York State Psychiatric Institute

Phone: 646-774-8069

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place